Related Experiment Videos
Calcium-channel blockers for combined angina pectoris and systemic hypertension
Insights
Calcium-channel blockers effectively treat both angina and hypertension. These medications offer a safe and favorable alternative to propranolol for patients with coexisting conditions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Calcium-channel blockers are established treatments for angina of effort and systemic hypertension.
- Many patients experience both angina pectoris and hypertension concurrently.
Purpose of the Study:
- To evaluate the safety and efficacy of calcium-channel blockers as monotherapy in patients with concomitant angina pectoris and hypertension.
- To compare the effectiveness of calcium-channel blockers with propranolol in this patient population.
Main Methods:
- Controlled clinical trials were conducted.
- The study involved patients with coexisting angina pectoris and hypertension.
Main Results:
- Calcium-channel blockers demonstrated safety and efficacy as monotherapy.
- Their effectiveness in hypertension is attributed to systemic vasodilation.
- In angina, they improve heart rate, blood pressure, contractility, and coronary blood flow.
Conclusions:
- Calcium-channel blockers are a valuable addition to treatment regimens for patients with coexisting angina and hypertension.
- Additional benefits like improved ventricular compliance and cardioprotection are under investigation.
Abstract:
Calcium-channel blockers have been successfully used in the treatment of angina of effort and systemic hypertension. Many patients present with concomitant angina pectoris and hypertension. Controlled clinical trials demonstrate that the calcium-channel blockers are safe and effective as monotherapy in the treatment of these patients, and that their use compares favorably with that of propranolol. The effectiveness of these agents in hypertension appears to be primarily due to their ability to induce systemic vasodilation. Calcium-channel blockers have several therapeutic effects in angina pectoris. Beneficial actions on the major determinants of oxygen consumption, i.e. heart rate, blood pressure and contractility, are generally seen. The potent coronary vasodilating actions of these agents allow for increased coronary blood flow. Improvements in ventricular compliance, regression of left ventricular hypertrophy and cardioprotection appear to be additional effects of the calcium-channel blockers; their contribution to the drugs' overall therapeutic efficacy is presently being evaluated. Calcium-channel blockers are a welcome addition to drug regimens available for the management of patients with coexisting angina pectoris and hypertension.